The estimated Net Worth of Michael Thomas Henderson is at least $9.53 Milione dollars as of 1 December 2020. Dr Henderson owns over 10,000 units of BridgeBio Pharma Inc stock worth over $7,955,066 and over the last 5 years he sold BBIO stock worth over $746,588. In addition, he makes $826,843 as Chief Bus. Officer at BridgeBio Pharma Inc.
Dr has made over 19 trades of the BridgeBio Pharma Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 10,000 units of BBIO stock worth $10,500 on 1 December 2020.
The largest trade he's ever made was exercising 22,813 units of BridgeBio Pharma Inc stock on 16 November 2020 worth over $10,494. On average, Dr trades about 6,720 units every 15 days since 2019. As of 1 December 2020 he still owns at least 284,211 units of BridgeBio Pharma Inc stock.
You can see the complete history of Dr Henderson stock trades at the bottom of the page.
Dr. Michael Thomas Henderson M.D. is the Chief Bus. Officer at BridgeBio Pharma Inc.
As the Chief Bus. Officer of BridgeBio Pharma Inc, the total compensation of Dr D at BridgeBio Pharma Inc is $826,843. There are 11 executives at BridgeBio Pharma Inc getting paid more, with Neil Kumar having the highest compensation of $26,334,100.
Dr D is 31, he's been the Chief Bus. Officer of BridgeBio Pharma Inc since . There are 19 older and 2 younger executives at BridgeBio Pharma Inc. The oldest executive at BridgeBio Pharma Inc is Dr. Charles J. Homcy M.D., 73, who is the Chairman of Pharmaceuticals & Lead Director.
Michael's mailing address filed with the SEC is C/O BRIDGEBIO PHARMA, INC., 421 KIPLING STREET, PALO ALTO, CA, 94301.
Over the last 5 years, insiders at BridgeBio Pharma Inc have traded over $409,396,563 worth of BridgeBio Pharma Inc stock and bought 12,280,644 units worth $209,241,115 . The most active insiders traders include Global Investors Lp Viking ..., Andrew Lo e Genetic Disorder L.P.Kkr Ge.... On average, BridgeBio Pharma Inc executives and independent directors trade stock every 12 days with the average trade being worth of $4,173,197. The most recent stock trade was executed by Neil Kumar on 16 August 2024, trading 55,537 units of BBIO stock currently worth $1,554,481.
we focus on accelerating and maximizing value in early-stage, genetic disease assets by applying our management expertise and proprietary platform. our team picks the right assets based on our systematic mapping of the genetic disease landscape, and develops those assets with the right approach, supporting r&d with expert capabilities and placing them in a value maximizing corporate structure.
BridgeBio Pharma Inc executives and other stock owners filed with the SEC include: